Comparative <i>in vitro</i> efficacy of aztreonam-avibactam and other alternatives (cefepime-taniborbactam, cefepime-zidebactam, and cefiderocol) against metallo-β-lactamase-producing Enterobacterales isolated in 2024 in France
We evaluated the <i>in vitro</i> activity of aztreonam-avibactam and other agents against 593 metallo-β-lactamase (MBL)-producing Enterobacterales collected in France in 2024. Aztreonam-avibactam showed the highest activity (98% susceptible), with resistance mainly observed in NDM-5-producing <i>Escherichia coli</i> belonging to ST167, ST405, and ST361. Cefepime-zidebactam also exhibited strong activity (96.6% of susceptibility). Cefepime-taniborbactam and cefiderocol showed reduced overall activity (76.4% and 74.9% susceptibility, respectively), with reduced efficacy mainly observed among NDM-producing isolates. Comparison with 1,465 isolates from 2023 showed no increase in aztreonam-avibactam resistance.
Authors
- M. Dutkiewicz
- Cécile Emeraud (ORCID: https://orcid.org/0009-0006-3595-6434)
- Laurent Dortet
Institutions
- Inserm (FR)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Université Paris-Saclay (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- CEA Paris-Saclay (FR)
- CNR de la Résistance aux Antibiotiques (FR)
- Comprehensive Clinical Research (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1128/aac.00176-26
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00